Eli Lilly stock rises after late-stage trial of next-generation weight-loss drug (opens original article in a new tab)

Eli Lilly stock rose following positive results from a late-stage trial of its next-generation weight-loss drug.

• Eli Lilly shares increased on Monday.
• A late-stage trial of the weight-loss drug received positive analyst reactions.